Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2011 Nov;152(5):715-6.
doi: 10.1016/j.ajo.2011.06.015.

Clinical evidence for neuroprotection in glaucoma

M Francesca Cordeiro, Leonard A Levin
Editorial

Clinical evidence for neuroprotection in glaucoma

M Francesca Cordeiro et al. Am J Ophthalmol. 2011 Nov.
No abstract available

PubMed Disclaimer

Comment on

References

    1. Chua B, Goldberg I. Neuroprotective agents in glaucoma therapy: Recent developments and future directions. Expert Rev Ophthalmol. 2010;5(5):627–636.
    1. Krupin T, Liebmann JM, Greenfield DS, Ritch R, Gardiner S. A randomized trial of brimonidine versus timolol in preserving visual function: Results from the Low-pressure Glaucoma Treatment Study. Am J Ophthalmol. Mar; in press. - PubMed
    1. Quaranta L, Gandolfo F, Turano R, et al. Effects of topical hypotensive drugs on circadian IOP, blood pressure, and calculated diastolic ocular perfusion pressure in patients with glaucoma. Investigative ophthalmology & visual science. 2006 Jul;47(7):2917–2923. - PubMed
    1. Liu JH, Medeiros FA, Slight JR, Weinreb RN. Diurnal and nocturnal effects of brimonidine monotherapy on intraocular pressure. Ophthalmology. 2010 Nov;117(11):2075–2079. - PubMed
    1. Collaborative Normal-Tension Glaucoma Study Group. Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. Am J Ophthalmol. 1998 Oct;126(4):487–497. - PubMed

MeSH terms